Embedded Files
FOCUSED PIPELINE ENTERING THE CLINIC
Our lead program, CFB-001, targets CIPN in patients receiving platinum based chemotherapy. We are building a focused pipeline of neuroprotective and restorative candidates for peripheral neuropathies.
LEAD PROGRAM
CIPN in platinum based chemotherapy; stage: pIND submission done Q1 2026. Phase 1a/1b planning.
FOLLOW-ON OPPORTUNITIES
Expansion into additional chemotherapies including taxanes and vinca alkaloids.
Expansion into other peripheral neuropathies including Diabetic, Radiation, and Compression Neuropathies.
ONE MECHANISM, MANY DISEASES: CFB-001 IS A POTENTIALLY DISEASE-MODIFYING NEUROSALVAGE PLATFORM
CFB-001 protects mitochondria - the shared root cause of nerve damage across multiple diseases, not just the symptoms of one.
CIPN is the lead indication and clinical proof point; the same peptide, the same topical mechanism, and the same potentially disease-modifying approach extends directly into other mitochondrial neuropathies - without new drug discovery.
Estimated US Patient Populations by Indication (bubble area is illustrative, not to exact scale)
1. CIPN: DelveInsight, CIPN Epidemiology Forecast, 2025 (US incident cases). 2. Diabetic peripheral neuropathy: ~34–38M US adults with diabetes (CDC/ADA) × up to ~50% neuropathy incidence (Pop-Busui et al., Diabetes Care, 2017). 3. Compression neuropathy: carpal tunnel + other entrapment neuropathies affect ~3–6% of US adults (AAFP, 2011). 4. Radiation-induced peripheral neuropathy: estimated from ~1M US patients receiving radiotherapy annually (ASTRO/AdvaMed; ~50% of cancer patients) × ~1–3% incidence of clinically significant plexopathy/neuropathy in high-risk fields (Applied Radiology, 2021; Neurology India, 2019).
Report abuse